Find trials
Consejos para buscar

A Study to Evaluate Gut Microbiome with POEMS Syndrome and Other Plasma Cell Disorders

Overview

Información sobre este estudio

The characteristics and role of gut microbiome rare plasma cell disorders- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) and amyloid light-chain (AL) amyloidosis, have not been explored; and their pathophysiology is quite elusive. To help understand rare plasma cell disorders and its association with gut microbiome, we will study the stool samples of newly diagnosed POEMS patients and AL amyloidosis and compare it with patients with newly diagnosed monoclonal gammopathy of undetermined significance and multiple myeloma as well as healthy controls. Moreover, gut microbiome in newly diagnosed POEMS patients will be compared to POEMS patients in remission. It is our overall hypothesis that in POEMS patients the gut microbiome signature will differ between active disease (at diagnosis) and inactive disease (in remission), and the gut microbiome in POEMS patients will be different from patients with other plasma cell disorders and healthy controls

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Men and women above 18 years of age.
  • Diagnosed with POEMS syndrome (newly diagnosed or in remission) or with newly diagnosed multiple myeloma (MM) or with monoclonal gammopathy of undetermined significance (MGUS) or amyloid light-chain (AL) amyloidosis or healthy controls from their households.

Exclusion Criteria:

  • Age under 18 years
  • Pregnancy
  • Substance abuse
  • Antibiotics use or gastrointestinal endoscopy in the 3 months prior to the study participation
  • Chronic gastrointestinal disorder
  • Gastrointestinal surgeries in the past 2 years  
  • Chemotherapy (including anti-plasma cell treatment and steroids) or radiation treatment for cancer within the last 2 years or active cancer (other than plasma cell disorder)

Eligibility last updated6/9/22. Questions regarding updates should be directed to the study team contact.

 

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Angela Dispenzieri, M.D.

Cerrado; inscripción por invitación

¿Qué es esto? (?)
"Close"
El estudio no está abierto para todos los que cumplen con los criterios de elegibilidad, sino solamente para las personas que el equipo del estudio ha invitado a participar.

Contact information:

Ann Engebretson L.P.N.

(507) 293-1965

Engebretson.Ann@mayo.edu

More information

Publicaciones

Publications are currently not available

Otros temas en investigación

.
CLS-20515796

Mayo Clinic Footer